Single Domain Intrabodies Against WASP Inhibit TCR-induced Immune Responses in Transgenic Mice T Cells

Overview

Journal Sci Rep

Specialty Science

Date 2013 Oct 22

PMID 24141565

Citations 4

Authors

Mitsuru Sato

Ryoko Sawahata

Chisato Sakuma

Takato Takenouchi

Hiroshi Kitani

Affiliations

Soon will be listed here.

Abstract

Intrabody technology provides a novel approach to decipher the molecular mechanisms of protein function in cells. Single domains composed of only the variable regions (V(H) or V(L)) of antibodies are the smallest recombinant antibody fragments to be constructed thus far. In this study, we developed transgenic (Tg) mice expressing the V(H) or V(L) single domains derived from a monoclonal antibody raised against the N-terminal domain of Wiskott-Aldrich syndrome protein (WASP), which is an adaptor molecule in immune cells. In T cells from anti-WASP V(H) and V(L) single domain Tg mice, interleukin-2 production induced by T cell receptor (TCR) stimulation were impaired, and specific interaction between the WASP N-terminal domain and the Fyn SH3 domain was strongly inhibited by masking the binding sites in WASP. These results strongly suggest that the V(H)/VL single domain intrabodies are sufficient to knockdown the domain function of target proteins in the cytosol.

Citing Articles

Development and validation of scFv-conjugated affinity silk protein for specific detection of carcinoembryonic antigen.

Sato M, Kitani H, Kojima K Sci Rep. 2017; 7(1):16077.

PMID: 29167497 PMC: 5700171. DOI: 10.1038/s41598-017-16277-6.

Utility of the dual-specificity protein kinase TTK as a therapeutic target for intrahepatic spread of liver cancer.

Miao R, Wu Y, Zhang H, Zhou H, Sun X, Csizmadia E Sci Rep. 2016; 6:33121.

PMID: 27618777 PMC: 5020615. DOI: 10.1038/srep33121.

Actin foci facilitate activation of the phospholipase C-γ in primary T lymphocytes via the WASP pathway.

Kumari S, Depoil D, Martinelli R, Judokusumo E, Carmona G, Gertler F Elife. 2015; 4.

PMID: 25758716 PMC: 4355629. DOI: 10.7554/eLife.04953.

A hybrid method for identification of structural domains.

Hua Y, Zhu M, Wang Y, Xie Z, Li M Sci Rep. 2014; 4:7476.

PMID: 25503992 PMC: 4265785. DOI: 10.1038/srep07476.

References

Steinberger P, Buhler B, Torbett B, Barbas 3rd C . Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc Natl Acad Sci U S A. 2000; 97(2):805-10. PMC: 15412. DOI: 10.1073/pnas.97.2.805. View

Remold-ODonnell E, Rosen F, Kenney D . Defects in Wiskott-Aldrich syndrome blood cells. Blood. 1996; 87(7):2621-31. View

Cattaneo A, Biocca S . The selection of intracellular antibodies. Trends Biotechnol. 1999; 17(3):115-21. DOI: 10.1016/s0167-7799(98)01268-2. View

Sawahata R, Sato M, Kitani H . Cytoplasmic expression and specific binding of the VH/VL single domain intrabodies in transfected NIH3T3 cells. Exp Mol Pathol. 2008; 86(1):51-6. DOI: 10.1016/j.yexmp.2008.11.005. View

Rao A, Luo C, Hogan P . Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol. 1997; 15:707-47. DOI: 10.1146/annurev.immunol.15.1.707. View

de la Fuente M, Sasahara Y, Calamito M, Anton I, Elkhal A, Gallego M . WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP). Proc Natl Acad Sci U S A. 2007; 104(3):926-31. PMC: 1783416. DOI: 10.1073/pnas.0610275104. View

Didenko V, Ngo H, Baskin D . Polyethyleneimine as a transmembrane carrier of fluorescently labeled proteins and antibodies. Anal Biochem. 2005; 344(2):168-73. PMC: 1853266. DOI: 10.1016/j.ab.2005.06.011. View

Badour K, Zhang J, Shi F, Leng Y, Collins M, Siminovitch K . Fyn and PTP-PEST-mediated regulation of Wiskott-Aldrich syndrome protein (WASp) tyrosine phosphorylation is required for coupling T cell antigen receptor engagement to WASp effector function and T cell activation. J Exp Med. 2004; 199(1):99-112. PMC: 1887720. DOI: 10.1084/jem.20030976. View

Tanaka T, Rabbitts T . Functional intracellular antibody fragments do not require invariant intra-domain disulfide bonds. J Mol Biol. 2008; 376(3):749-57. DOI: 10.1016/j.jmb.2007.11.085. View

10.

Stocks M . Intrabodies as drug discovery tools and therapeutics. Curr Opin Chem Biol. 2005; 9(4):359-65. DOI: 10.1016/j.cbpa.2005.06.003. View

11.

Heng B, Cao T . Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: potential advantages over antibodies expressed within the intracellular environment (Intrabody). Med Hypotheses. 2005; 64(6):1105-8. DOI: 10.1016/j.mehy.2005.01.011. View

12.

Sato M, Tsuji N, Gotoh H, Yamashita K, Hashimoto K, Tadotsu N . Overexpression of the Wiskott-Aldrich syndrome protein N-terminal domain in transgenic mice inhibits T cell proliferative responses via TCR signaling without affecting cytoskeletal rearrangements. J Immunol. 2001; 167(8):4701-9. DOI: 10.4049/jimmunol.167.8.4701. View

13.

HAMERS-CASTERMAN C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa E . Naturally occurring antibodies devoid of light chains. Nature. 1993; 363(6428):446-8. DOI: 10.1038/363446a0. View

14.

Munro S, Pelham H . An Hsp70-like protein in the ER: identity with the 78 kd glucose-regulated protein and immunoglobulin heavy chain binding protein. Cell. 1986; 46(2):291-300. DOI: 10.1016/0092-8674(86)90746-4. View

15.

Sato M, Sawahata R, Takenouchi T, Kitani H . Identification of Fyn as the binding partner for the WASP N-terminal domain in T cells. Int Immunol. 2011; 23(8):493-502. DOI: 10.1093/intimm/dxr042. View

16.

Lobato M, Rabbitts T . Intracellular antibodies and challenges facing their use as therapeutic agents. Trends Mol Med. 2003; 9(9):390-6. DOI: 10.1016/s1471-4914(03)00163-1. View

17.

Alvarez R, Barnes M, Gomez-Navarro J, Wang M, Strong T, Arafat W . A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin Cancer Res. 2000; 6(8):3081-7. View

18.

Holt L, Herring C, Jespers L, Woolven B, Tomlinson I . Domain antibodies: proteins for therapy. Trends Biotechnol. 2003; 21(11):484-90. DOI: 10.1016/j.tibtech.2003.08.007. View

19.

Bird R, HARDMAN K, Jacobson J, Johnson S, Kaufman B, Lee S . Single-chain antigen-binding proteins. Science. 1988; 242(4877):423-6. DOI: 10.1126/science.3140379. View

20.

Marasco W, Haseltine W, Chen S . Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc Natl Acad Sci U S A. 1993; 90(16):7889-93. PMC: 47248. DOI: 10.1073/pnas.90.16.7889. View